Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × NSCLC × Gemcitabine × Clear all

Phase

Status

Terminated 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 53 Nasopharyngeal Carcinoma 22 Cholangiocarcinoma 19 Biliary Tract Neoplasms 19 Urinary Bladder Neoplasms 18 Carcinoma, Non-Small-Cell Lung 16 Neoplasm Metastasis 14 Breast Neoplasms 13 Lung Neoplasms 12 Carcinoma, Transitional Cell 11 Lymphoma, Large B-Cell, Diffuse 10 Colorectal Neoplasms 10 Recurrence 9 Non-Muscle Invasive Bladder Neoplasms 9 Sarcoma 8 Neoplasms 6 Hodgkin Disease 6 Gallbladder Neoplasms 6 Ovarian Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4 Nasopharyngeal Neoplasms 4 Leiomyosarcoma 4 Triple Negative Breast Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Adenocarcinoma 3 Osteosarcoma 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, B-Cell 3 Lymphoma 3

Interventions

Drug Therapy 4 Radiotherapy 3 Pemetrexed 3 Carboplatin 3 osimertinib 2 aflutinib 2 Radiosurgery 2 trilaciclib 1 toripalimab 1 tislelizumab 1 sugemalimab 1 spartalizumab 1 sintilimab 1 pembrolizumab 1 cemiplimab 1 Vinorelbine 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Chemotherapy, Adjuvant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06576635 2026-01-20

LUNG-05

University of Illinois at Chicago

Phase NA Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡